DGAP-News

MOLOGEN AG: Successful financing and continuation of clinical studies with the lead product lefitolimod in the first quarter 2017

DGAP-News: MOLOGEN AG / Key word(s): Quarterly / Interim Statement MOLOGEN AG: Successful financing and continuation of clinical studies with the lead product lefitolimod in the first quarter 2017 11.05.2017 / 07:00 The issuer is solely responsible for the content of this announcement. Press release N 10 / 2017 as of 11 May 2017

MOLOGEN AG: Successful financing and continuation of clinical studies with the lead product lefitolimod in the first quarter 2017

- Ongoing implementation of the "Next Level" corporate strategy

- Funding secured until the start of 2018 through additional capital measure

- Further progress in clinical studies with lead product lefitolimod

- Preparations for possible out-licensing of lefitolimod

- Dr Matthias Baumann appointed as new Chief Medical Officer

- Outlook for 2017 confirmed

Berlin, 11 May 2017 - In line with the "Next Level" corporate strategy, which was adopted last year, the operational focus of MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) remained on the continuation of four clinical studies with the lead product, the immunotherapy lefitolimod, in the first quarter of 2017. MOLOGEN has made further significant progress over the past few months: patient recruitment for the phase III IMPALA pivotal study in the indication colorectal cancer was further advanced and is currently in the closing stages. In April 2017, MOLOGEN published key findings from the exploratory IMPULSE phase II trial in the indication small cell lung cancer. The extension phase of the phase I/II TEACH study in the indication HIV and the phase I combination study with the checkpoint inhibitor Yervoy^(R) in collaboration with MD Anderson Cancer Center at the University of Texas, U.S., continued. As expected, the study advancements resulted in a slight increase in expenses in the area of research and development.